Table 2.
Efficacy outcome measurements
| Study | Study arm | MPR | pCR |
|---|---|---|---|
| Monotherapy–ICI | |||
| Range over all studies | 0%-45% | 7%-16% | |
| Tong et al.25, n (%) | 7/25 (28) | 3/25 (12) | |
| Eichhorn et al.14, n (%) | 4/15 (27) | 2/15 (13) | |
| Lee et al.18, n (%) | 30/147 (20)a | 10/147 (7)a | |
| Gao et al.16, n (%) | 15/37 (40.5) | 6/37 (16) | |
| Besse et al.13, n (%) | 0/30 (0) | NR | |
| Forde et al.15, n (%) | 9/20 (45) | 3/20 (15) | |
| Dual–ICI | |||
| Cascone et al.27, n (%) | Nivo Ipi/nivo |
5/21 (24) 8/16 (50) |
2/21 (9.5) 6/16 (38) |
| Reuss et al.20, n (%) | NR | 2/6 (33) | |
| Chemotherapy with ICI | |||
| Range over all studies | 27%-86% | 9%-63% | |
| Rothschild et al.21, n (%) | 34/55 (62) | 10/55 (18) | |
| Zhao et al.11, n (%) | 20/30 (66) | 15/30 (50) | |
| Forde et al.10 and Spicer et al.12, n (%) | Nivo + chemo Chemo alone |
66/179 (37) 4/179 (2) |
43/179 (24) 16/179 (9) |
| Shen et al.22, n (%) | 24/37 (65) | 17/37 (46) | |
| Lei et al.29, n (%) | Cam + chemo | 6/7 (86) | 4/7 (57) |
| Chemo alone | 2/6 (33) | 1/6 (17) | |
| Shu et al.23, n (%) | 17/26 (65) | 10/26 (38) | |
| Provencio et al.19, n (%) | 34/41 (83) | 26/41 (63) | |
| Tfayli et al.24, n (%) | 3/11 (27) | 1/11 (9) | |
| Yang et al.26, n (%) | NR | 2/13 (15) | |
| Chemoradiotherapy with ICI | |||
| Hong et al.17, n (%) | 8/11 (73) | 3/11 (27) | |
| Radiotherapy with ICI | |||
| Altorki et al.28, n (%) | Durva Durva + SBRT |
2/30 (7) 16/30 (53) |
0/30 (0) 8/30 (27) |
Cam, camrelizumab; Chemo, chemotherapy; Durva, durvalumab; ICI, immune checkpoint inhibitor; Ipi/nivo, ipilimumab/nivolumab; MPR, major pathological response; Nivo, nivolumab; NR, not reported; pCR, pathological complete response; SBRT, stereotactic body radiotherapy.
a
Patients with oncogenic driver mutations were excluded from pathological evaluations.